Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: J Glaucoma. 2022 Jul 21;31(10):e105. doi: 10.1097/IJG.0000000000002087

Reply to Letter: Letter-to-the-Editor: The association between regional macula vessel density and central visual field damage in advanced glaucoma eyes

Elham Ghahari 1, Sasan Moghimi 1, Robert N Weinreb 1
PMCID: PMC9529871  NIHMSID: NIHMS1822647  PMID: 35882043

Although the findings are similar in the two studies, the study populations are very different. Dr. Hollo1 included only 27 primary open angle glaucoma (POAG), 14 ocular hypertensive, and 9 healthy eyes. He did not include the numbers of patients in each stage of disease, and only mentioned the visual field (VF) mean deviation (MD) ranging from early to advanced. [VF MD (median, quartiles): −6.5 (−2.6, −17.2)].

In contrast, we studied advanced glaucoma eyes and demonstrated a regional and global structure-function relationship between macular vessel density and 10–2 VF sensitivity.2 All 44 eyes of our study group had MD<−10 dB. It has been shown that especially retinal nerve fiber layer thickness reaches the floor at visual Field MD <−10 dB and thus the structure-function relationship varies across the glaucoma continuum. This is in line with our prior studies in which global associations between whole macula and parafoveal vessel densities and 24–2 VF MD in advanced disease have been reported3. Moreover, we have shown that in advanced glaucoma, particularly when VF MD is worse than −14 dB, OCTA-measured pfVD is a promising tool for monitoring progression because it does not have a detectable measurement floor4.

We thank Dr. Hollo for his interest in our study.

Funding Support:

National Institutes of Health/National Eye Institute Grants R01EY029058, Core Grant P30EY022589; and an Unrestricted Grant from Research to Prevent Blindness (New York, NY).

Footnotes

Commercial Disclosures:

1 Elham Ghahari: none

2 Sasan Moghimi: none

3 Robert N. Weinreb: C: Aerie Pharmaceuticals, Allergan, Eyenovia, Topcon; F: Heidelberg Engineering, Centervue, Optovue, Topcon, Carl Zeiss Meditec Inc., Research to Prevent Blindness (New York, NY), National Eye Institute.

References:

  • 1.Gahar G , Bowd C, Zangwill L, Proudfoot J, Penteado R, Kyung H, Hou H, Moghimi S, Weinreb R. The association between regional macula vessel density and central visual field damage in advanced glaucoma eyes. J Glaucoma, Publish Ahead of Print 03. June 2022, DOI: 10.1097/IJG.0000000000002055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Holló G Comparison of thickness – function and vessel density – function relationship in the superior and inferior macula, and the superotemporal and inferotemporal peripapillary sectors. J Glaucoma 2020; 29: 168–174. [DOI] [PubMed] [Google Scholar]
  • 3.Ghahari E, Bowd C, Zangwill LM, Proudfoot J, Hasenstab KA, Hou H, Penteado RC, Manalastas PIC, Moghimi S, Shoji T, Christopher M, Yarmohammadi A, Weinreb RN. Association of Macular and Circumpapillary Microvasculature with Visual Field Sensitivity in Advanced Glaucoma. Am J Ophthalmol 2019;204:51–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Moghimi S, Bowd C, Zangwill LM, Penteado RC, Hasenstab K, Hou H, Ghahari E, Manalastas PIC, Proudfoot J, Weinreb RN. Measurement Floors and Dynamic Ranges of OCT and OCT Angiography in Glaucoma. Ophthalmology 2019;126(7):980–988. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES